Summary of Key Points Core Viewpoint - Green Bamboo Bio-B (02480.HK) reported a significant decrease in other income and R&D expenses, while also showing a reduction in pre-tax losses for the six months ending June 30, 2025, primarily due to decreased government subsidies and clinical trial costs [1]. Financial Performance - Other income decreased by approximately 50.2% to around RMB 4.9 million, mainly due to a reduction in government subsidies [1]. - R&D expenses decreased by approximately 37.5% from about RMB 80.4 million for the six months ending June 30, 2024, to about RMB 50.3 million for the same period in 2025, primarily due to reduced costs associated with the LZ901 Phase III clinical trial in China [1]. - Pre-tax losses decreased by approximately 29.4% from about RMB 109.9 million for the six months ending June 30, 2024, to about RMB 77.6 million for the same period in 2025 [1].
绿竹生物-B(02480.HK)中期研发开支减少约37.5%至约5030万元